story of the week
Time for Personalized Dosing of Natalizumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Neurology, Neurosurgery, and Psychiatry
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)
J. Neurol. Neurosurg. Psychiatr. 2023 Nov 14;[EPub Ahead of Print], AA Toorop, ZY van Lierop, LM Gelissen, E Hoitsma, EM Zeinstra, LC van Rooij, CE van Munster, A Vennegoor, JP Mostert, BH Wokke, NF Kalkers, EL Hoogervorst, JJ van Eijk, CM Roosendaal, JJ Kragt, M Eurelings, J van Genugten, J Nielsen, L Sinnige, ME Kloosterziel, EP Arnoldus, GW van Dijk, WH Bouvy, MH Wessels, L Boonkamp, EM Strijbis, BW van Oosten, BA De Jong, BI Lissenberg-Witte, F Barkhof, B Moraal, CE Teunissen, T Rispens, BM Uitdehaag, J Killestein, ZL van KempenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.